Articles
Although small, the US Food and Drug Administration (FDA) has identified an increased risk for developing anaplastic large cell lymphoma (ALCL) in the scar capsule adjacent to breast implants. Because the risk is small, pharmacists can help assure women that FDA-approved breast implants are safe when used correctly.
Everolimus plus octreotide LAR increases median progression-free survival over octreotide LAR alone in patients with advanced neuroendocrine tumors (NETs), according to the updated results of the RAD001 In Advanced Neuroendocrine Tumors (RADIANT-2) trial presented at the 2011 Gastrointestinal Cancers Symposium (Abstract 159).
Nimotuzumab shows the potential to improve both progression-free survival (PFS) and overall survival (OS) in patients with epidermal growth factor receptor (EGFR)-positive gastric cancer, according to results of a phase 2 randomized trial presented at the Gastrointestinal Cancers Symposium.
By repeating therapy cycles, clivatuzumab tetraxetan labeled with 90Y plus low-dose gemcitabine improve overall survival (OS) over single-cycle therapy in patients with locally advanced or metastatic pancreatic cancer, according to updated data presented at the Gastrointestinal Cancers Symposium. Researchers also found that as the 90Y labeld clivatuzumab tetraxetan dose increased so did median OS.
A unique partnership will offer an opportunity for patients to attain breakthrough cancer pain medication in the retail setting. ProStakan—the manufacturer of Abstral, a fentynal immediate-release transmucosal tablet—has leveraged RelayHealth’s pharmacy network and McKesson Specialty Care Solutions’ experience in administering risk mitigation and management strategies (REMS) programs to make the agent more readily available for patients.
Two-thirds of patients achieved stable disease with sorafenib after resistance to imatinib and sunitinib treatment for gastrointestinal stromal tumors (GIST), according to a phase 2 trial to be presented at the Gastrointestinal Cancers Symposium.
Two-thirds of patients achieved stable disease with sorafenib after resistance to imatinib and sunitinib treatment for gastrointestinal stromal tumors (GIST), according to a phase 2 trial to be presented at the Gastrointestinal Cancers Symposium.
When choosing a day cream, patients may not realize that many products do not provide adequate protection against long-range UV-A1 rays, something pharmacy education can help remedy. A new study of 29 popular facial moisturizers finds that, although labeling suggests broad-spectrum UV coverage, only 23 products contained active ingredients with UV-A1 protection, some in low concentrations (Arch Dermatol. Epub January 17, 2011).
Combining two kinds of targeted agents—a PI3K/AKT inhibitor and agents that target epigenetic changes—may improve therapy for breast cancer in the future, according to researchers at Ohio State University.
With just one third of the standard dose of cisplatin, researchers successfully shrank tumors in mice, without sacrificing efficacy. They were able to do this by encapsulating the prodrug form of the agent in a nanoparticle, which they then targeted to prostate tumor cells.
Because less drug is used, the hope is that potentially severe side effects will be reduced, for cisplatin, the kidney and nerve damage.